Skip to main content
Premium Trial:

Request an Annual Quote

Rudy Potenzone, Per Artur Peterson, Robert Kolodner

Premium
Rudy Potenzone has joined Microsoft as worldwide industry technology strategist for pharmaceuticals. Potenzone was most recently vice president for enterprise solutions at CambridgeSoft. Prior to that, he served as vice president of product management at Ingenuity, president of Lion Biosciences US, senior vice president of research and development at MDL, and director of new product development and research for the American Chemical Society.
 

 
Entelos has appointed Per Artur Peterson to its board as a non-executive director. Peterson recently retired as chairman of research and development at Johnson & Johnson, where he was responsible for J&J’s corporate office of science and technology, the enterprise-wide R&D council, and J& J’s cell therapy research activities.
 
Peterson joined J&J’s R.W. Johnson Pharmaceutical Research Institute in 1994 as vice president of drug discovery. Prior to that, he spent eight years at Scripps Research Institute, where he led the division of molecular immunogenetics before being appointed chairman of the department of immunology in 1987. He also served as director of the Wallenberg Laboratory and as professor of cell biology at the University of Uppsala.
 

 
The US Department of Health and Human Services has appointed Robert Kolodner as head of the Office of the National Coordinator for Health Information Technology. Kolodner has been serving as interim coordinator since September [BioInform 09-29-06].  
 
Kolodner joined HHS from the Department of Veterans Affairs' Veterans Health Administration, where he was chief health informatics officer. 

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.